Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options!
**🌟 A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options! 🌟**
Cancer cell
📆CANCER CELL
January 5, 2023: The highly anticipated Phase 3 pivotal clinical trial (ASTRUM-004) of HANSIZHUANG, an anti-PD-1 monoclonal antibody developed independently by Henlius, in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC), has just been published in the prestigious international oncology journal “Cancer Cell” (Impact Factor: 50.3)! Led by Professor Zhou Caicun from Shanghai Pulmonary Hospital, this milestone study signifies a significant breakthrough in lung cancer treatment.
🔬 Lung cancer
is one of the most common cancers globally, with the highest reported incidence and mortality rates in China. According to the latest statistics from the National Cancer Center, there are 828,000 new cases of lung cancer and 657,000 deaths annually. Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancers, with a significant proportion diagnosed at an advanced stage or with metastasis, unsuitable for surgical resection.
🌱NSCLC
In the field of NSCLC treatment, immune checkpoint inhibitors have become a game-changer. Serplulimab is the first innovative monoclonal antibody developed independently by Henlius. Since its approval in March 2022, it has been approved in China for the treatment of microsatellite instability-high (MSI-H) solid tumors, sqNSCLC, extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), benefiting over 51,000 patients.
🔍 ASTRUM-004
is a pivotal Phase 3 trial aimed at evaluating the efficacy and safety of serplulimab in combination with chemotherapy as first-line treatment for advanced sqNSCLC. The results are promising: patients receiving serplulimab demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS), with manageable safety profiles.
Serplulimab
🎉NEW ERA
These findings herald a new era in lung cancer treatment, offering a ray of hope for patients and clinicians alike. Serplulimab in combination with chemotherapy has emerged as a promising first-line treatment option, bringing innovation and reliability to sqNSCLC patients.
👩🔬Lead
Lead investigator Professor Zhou Caicun commented, “The ASTRUM-004 study validates the significant potential of serplulimab in combination with chemotherapy to improve survival outcomes in sqNSCLC patients, marking a major breakthrough in the field of lung cancer.”
🌟 Stay tuned for more updates as we continue to unravel the mysteries of cancer treatment, bringing hope to millions worldwide!
#CancerResearch #LungCancer #MedicalBreakthrough #InnovationForHealth #Serplulimab #NSCLC #ASTRUM #sqNSCLC #cancercell